CO2023013510A2 - Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un agente quimioterapéutico - Google Patents
Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un agente quimioterapéuticoInfo
- Publication number
- CO2023013510A2 CO2023013510A2 CONC2023/0013510A CO2023013510A CO2023013510A2 CO 2023013510 A2 CO2023013510 A2 CO 2023013510A2 CO 2023013510 A CO2023013510 A CO 2023013510A CO 2023013510 A2 CO2023013510 A2 CO 2023013510A2
- Authority
- CO
- Colombia
- Prior art keywords
- chemotherapeutic agent
- treating
- antibody
- prolgolimab
- carboplatin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000002246 antineoplastic agent Substances 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 5
- 229930012538 Paclitaxel Natural products 0.000 abstract 4
- 229960004562 carboplatin Drugs 0.000 abstract 4
- 190000008236 carboplatin Chemical compound 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 4
- 229960001592 paclitaxel Drugs 0.000 abstract 4
- 229940121482 prolgolimab Drugs 0.000 abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 4
- 230000036210 malignancy Effects 0.000 abstract 3
- 229960000397 bevacizumab Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al uso del anticuerpo contra PD-1, en particular prolgolimab, en combinación con al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna en un sujeto que la necesita, y al uso del anticuerpo contra PD-1 prolgolimab en combinación con el anticuerpo contra VEGF, en particular bevacizumab, y al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna en un sujeto que lo necesita. La presente invención se refiere además a un método para tratar una neoplasia maligna en un sujeto que la necesita, que comprende administrar una cantidad terapéuticamente eficaz de anticuerpo contra PD-1, en particular prolgolimab, en combinación con al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, y a un método para tratar una neoplasia maligna en un sujeto que la necesita, que comprende administrar una cantidad terapéuticamente eficaz del anticuerpo contra PD-1 prolgolimab en combinación con el anticuerpo contra VEGF, en particular bevacizumab, y al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021109765A RU2787457C2 (ru) | 2021-04-08 | Способ лечения злокачественного новообразования с использованием комбинации антитела к pd-1 и химиотерапевтического агента | |
| PCT/RU2022/050122 WO2022216184A1 (en) | 2021-04-08 | 2022-04-08 | Malignant neoplasis treatment using pd-1 antibody combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023013510A2 true CO2023013510A2 (es) | 2023-11-10 |
Family
ID=83546621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0013510A CO2023013510A2 (es) | 2021-04-08 | 2023-10-12 | Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un agente quimioterapéutico |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4319736A1 (es) |
| CN (1) | CN117500493A (es) |
| AR (1) | AR125322A1 (es) |
| BR (1) | BR112023020856A2 (es) |
| CL (1) | CL2023003012A1 (es) |
| CO (1) | CO2023013510A2 (es) |
| EC (1) | ECSP23076237A (es) |
| MA (1) | MA62924A1 (es) |
| MX (1) | MX2023011952A (es) |
| TW (1) | TW202304511A (es) |
| UY (1) | UY39724A (es) |
| WO (1) | WO2022216184A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0609957A2 (pt) * | 2005-05-12 | 2010-05-11 | Pfizer | uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer |
| WO2020226986A2 (en) * | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
-
2022
- 2022-04-08 UY UY0001039724A patent/UY39724A/es unknown
- 2022-04-08 CN CN202280027483.7A patent/CN117500493A/zh active Pending
- 2022-04-08 MA MA62924A patent/MA62924A1/fr unknown
- 2022-04-08 EP EP22785065.8A patent/EP4319736A1/en active Pending
- 2022-04-08 TW TW111113464A patent/TW202304511A/zh unknown
- 2022-04-08 WO PCT/RU2022/050122 patent/WO2022216184A1/en active Application Filing
- 2022-04-08 BR BR112023020856A patent/BR112023020856A2/pt unknown
- 2022-04-08 AR ARP220100896A patent/AR125322A1/es unknown
- 2022-04-08 MX MX2023011952A patent/MX2023011952A/es unknown
-
2023
- 2023-10-06 CL CL2023003012A patent/CL2023003012A1/es unknown
- 2023-10-06 EC ECSENADI202376237A patent/ECSP23076237A/es unknown
- 2023-10-12 CO CONC2023/0013510A patent/CO2023013510A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4319736A1 (en) | 2024-02-14 |
| UY39724A (es) | 2022-10-31 |
| MX2023011952A (es) | 2023-11-09 |
| CL2023003012A1 (es) | 2024-04-12 |
| WO2022216184A1 (en) | 2022-10-13 |
| AR125322A1 (es) | 2023-07-05 |
| CN117500493A (zh) | 2024-02-02 |
| BR112023020856A2 (pt) | 2024-02-06 |
| MA62924A1 (fr) | 2024-03-29 |
| TW202304511A (zh) | 2023-02-01 |
| ECSP23076237A (es) | 2024-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022013599A2 (es) | Anticuerpos anti-ccr8 para el tratamiento del cáncer | |
| BR112021022812A2 (pt) | Dosagem de inibidor de kras para tratamento de cânceres | |
| CL2019000585A1 (es) | Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos. | |
| ECSP17014159A (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
| CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| UA116095C2 (uk) | Застосування пертузумабу, трастузумабу і хіміотерапії на основі карбоплатину для неоад'ювантного лікування her2-позитивного раку молочної залози ранньої стадії у пацієнта | |
| MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| BR112018016054A2 (pt) | composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo | |
| ECSP22057324A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| CR20170529A (es) | Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2. | |
| EA201992573A1 (ru) | Лечение her2-положительных злокачественных новообразований | |
| CL2023000741A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos. | |
| BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. | |
| NI201500100A (es) | Mãtodos de tratamiento de la deficiencia de hierro con pirofosfato fãrrico soluble | |
| AR119507A1 (es) | Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3 | |
| CO2023013510A2 (es) | Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un agente quimioterapéutico | |
| CL2021002966A1 (es) | Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer. | |
| DOP2023000230A (es) | Anticuerpo biespecífico anticldn4/anticd137 | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| MX2021014486A (es) | Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo. | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| BR112023004830A2 (pt) | Métodos para tratamento de mieloma múltiplo |